Actively Recruiting
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
Led by OHSU Knight Cancer Institute · Updated on 2026-05-08
250
Participants Needed
1
Research Sites
198 weeks
Total Duration
On this page
Sponsors
O
OHSU Knight Cancer Institute
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This clinical trial tests the effectiveness of an online weight loss plus resistance training intervention (iLIVE) to decrease obesity and improve frailty in men with prostate cancer who received androgen deprivation therapy (ADT). Androgen deprivation therapy increases the risk of frailty, weight gain and obesity in prostate cancer survivors. The combination of frailty and obesity can lead to a decrease in quality of life and an increased risk of recurrent falls. Using iLIVE may improve obesity and frailty in men with prostate cancer who receive ADT.
CONDITIONS
Official Title
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with histologically confirmed prostate cancer
- Received at least 6 months of androgen deprivation therapy within the past 10 years
- Completed radiotherapy, chemotherapy, and/or surgery more than 6 weeks prior to enrollment
- No plans to start adjuvant chemotherapy or radiotherapy within 6 months of enrollment
- Overweight or obese with body mass index over 25 kg/m2 up to 50
- Shows evidence of frailty by meeting three or more criteria: weakness, slowness, fatigue, inactivity, or illness
- Not currently involved in a structured diet or resistance strength training program
- Willing to be randomized and follow the study protocol
- Have home internet sufficient for videoconferencing
- Signed informed consent
- For implementation participants: be a key stakeholder such as a healthcare provider, administrator, or study participant
- For implementation participants: provided verbal informed consent after receiving information sheet
You will not qualify if you...
- Unintentional weight loss greater than 5% within the last year
- Contraindications to moderate intensity exercise
- Health conditions affecting weight or body composition such as Cushing's syndrome or uncontrolled thyroid disorders
- Active malignancy other than non-melanoma skin cancer
- Not fluent in English and unable to complete surveys or follow study instructions in English
- Currently taking or have taken creatine supplements in the month before baseline testing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
OHSU Knight Cancer Institute
Portland, Oregon, United States, 97239
Actively Recruiting
Research Team
C
Carolyn Guidarelli, MPH
CONTACT
S
Sharon McCoy, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here